MétaCan
Menu
← Back to cohort
Record W4391579913 · doi:10.1101/2024.02.02.24302227

Short- and long-term effects of imatinib in patients hospitalised for COVID-19 infection: A randomised controlled trial

2024· preprint· en· W4391579913 on OpenAlexaff
Alex L E Halme, Sanna Laakkonen, Jarno Rutanen, Olli Nevalainen, Marjatta Sinisalo, Saana Horstia, Jussi M. J. Mustonen, Negar Pourjamal, Aija Vanhanen, Solidarity Finland Investigators, Tuomas Rosberg, Andreas Renner, Markus Perola, Erja‐Leena Paukkeri, Riitta-Liisa Patovirta, Seppo Parkkila, Juuso Paajanen, Taina Nykänen, Jarkko Mäntylä, Marjukka Myllärniemi, Tiina Mattila, Maarit K. Leinonen, Alvar Külmäsu, Pauliina Kuutti, Ilari Kuitunen, Hanna‐Riikka Kreivi, Tuomas P. Kilpeläinen, Heikki Kauma, Ilkka Kalliala, Petrus Järvinen, Riina Hankkio, Taina Hammarén, Thijs Feuth, Hanna Ansakorpi, Riikka Ala-Karvia, Gordon H. Guyatt, Kari A.O. Tikkinen

Bibliographic record

VenuemedRxiv · 2024
Typepreprint
Languageen
FieldMedicine
TopicCOVID-19 Clinical Research Studies
Canadian institutionsMcMaster UniversityImpact
FundersHengityssairauksien TutkimussäätiöFilhaTampereen TuberkuloosisäätiöTaysSuomen Lääketieteen SäätiöSigrid Juséliuksen SäätiöPäivikki ja Sakari Sohlbergin SäätiöWorld Health Organization
KeywordsMedicineImatinibInternal medicineRandomized controlled trialCoronavirus disease 2019 (COVID-19)Quality of life (healthcare)PediatricsDisease

Abstract

fetched live from OpenAlex

Abstract We report the short- and long-term results of the SOLIDARITY Finland on mortality and other patient-important outcomes in patients hospitalised for COVID-19. Between 08/2021 and 03/2023, we randomised 156 patients in 15 hospitals. In the imatinib group, 7.2% of patients had died at 30 days and 13.3% at 1 year and in the standard of care group 4.1% and 8.3% (adjusted HR at 30 days 1.09, 95% CI 0.23–5.07). In a meta-analysis of randomised trials of imatinib versus standard of care (n=732), allocation to imatinib was associated with a mortality risk ratio of 0.73 (95% CI 0.32–1.63). At 1-year, self-reported recovery occurred in 79.0% in imatinib and in 88.3% in standard of care (RR 0.91, 95% CI 0.78-1.06). Of the 21 potential long COVID symptoms, patients often reported moderate or major bother from fatigue (24%), sleeping problems (19%) and memory difficulties (17%). We found no convincing difference between imatinib and standard of care groups in quality of life or symptom outcomes. The evidence raises serious doubts regarding the benefit of imatinib in reducing mortality, improving recovery, and preventing potential long COVID symptoms when given to patients hospitalised for COVID-19.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.006
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.006
Threshold uncertainty score0.020

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.006
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0040.006
Bibliometrics0.0000.001
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0030.003
Insufficient payload (model declined to judge)0.0060.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.038
GPT teacher head0.418
Teacher spread0.380 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2024
Admission routes1
Has abstractyes

Explore more

Same venuemedRxiv→Same topicCOVID-19 Clinical Research Studies→French-language works237,207→